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Behçet’s disease (BD) is a complex inflammatory disease, of unknown etiology. While
disease pathogenesis remains unclear, a strong relationship between BD and HLA-B*51
has been established over the last 30 years. A number of theories exist regarding the
cause of BD; however, few are able to account for the increased rates of HLA-B*51 pos-
itive individuals, particularly around the Mediterranean basin and Middle-East where the
prevalence is highest. This review outlines current immunogenetic data on BD and the
immunoregulatory role natural killer cells may play. It also describes the interaction of the
killer immunoglobulin-like receptor – KIR3DL1 with its ligand Bw4, which is found on HLA-
B51. Finally, CD94/NKG2D, MICA, and ERAP are outlined with regard to their potential roles
in BD.
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BEHÇET’S DISEASE
Behçet’s disease (BD) is a complex systemic inflammatory disorder,
consisting of oral aphthous ulcers, genital ulcers, papulopustular
and erythema nodosum-like skin lesions, uveitis, retinal vasculitis,
thrombophlebitis, arterial aneurysms, and arthritis. The disease is
found primarily along the ancient Silk Route from the Mediter-
ranean Basin across Asia to Japan (1, 2). The prevalence of BD
in UK is around 0.64/100,000, whereas in Istanbul 370/100,000
individuals are affected by this disease (3).
NATURAL KILLER CELL BIOLOGY
Natural killer (NK) cells are lymphocytes of the innate immune
system. They are involved in the early stages of defense against for-
eign and self-cells undergoing stress. NK cells comprise 10–15%
circulating lymphocytes in humans, falling mostly into two dis-
tinct populations. About 90% are CD56dimCD16+ve cells, capable
of killing and antibody dependent cytotoxicity. These cells produce
relatively little IFNγ (4, 5). NK cells identify their targets through a
set of activatory or inhibitory receptors, which recognize non-self
targets as well as self-proteins that are upregulated as a result of
stress. They can also kill cells that down regulate expression of self-
MHC molecules during times of infection or transformation (6,7).
The other 10% are CD56brightCD16−ve and are weakly cyto-
toxic. These cells do not proliferate vigorously in response to
IL-2, but produce substantial amounts of IFNγ, granulocyte–
macrophage colony-stimulating factor (GM-CSF), chemokines
such as chemokine ligand 3 (CCL3) and CCL4 (8). It has been
suggested that CD56brightCD16−ve cells utilize their cytokine pro-
duction to play a regulatory role in immune responses while
CD56dimCD16+ve cells are terminally differentiated cytotoxic
effector cells (9).
Natural killer cells express a number of activatory and
inhibitory receptors. Killer immunoglobulin-like receptors (KIR)
and NKG2D are discussed in detail below with respect to their
role in BD. Natural cytotoxicity receptors (NCR) are activatory
receptors found on NK cells. There are three known receptors;
NKp46, NKp30, and NKp44. NKp46 and NKp30 are constitutively
expressed, whereas NKp44 is expressed during NK cell activation
by IL-2 (10, 11). NCR have been investigated in the context of
tumor biology and cytokine production; however, they do not
interact directly with class-I ligands and there is limited evidence
for their role in autoimmune/autoinflammatory disease.
IL-15 and IL-15Rα are essential for normal development of
naive CD8+ve T cells, intestinal intraepithelial lymphocytes, and
NK cells. IL-15 shares structural similarity with IL-2 and both
cytokines signal through CD122 to increase proliferation of NK
cells (12).
Elevated IL-15 levels have been reported in serum, cere-
brospinal fluid, and aqueous humor from patients with BD (13–
15). Serum IL-15 levels have been found to correlate with ery-
throcyte sedimentation rate but not C-reactive protein levels and
IL-15Rα expression has been found to be significantly reduced
in leukocytes from patients compared to controls (12). While
these findings suggest a possible role for IL-15 in BD patho-
genesis, the mechanism remains unclear. It would be useful to
establish whether there is a link between BD clinical activity and
serum/organ specific IL-15/IL-15Rα levels. The effect of altered
levels of IL-15 and the IL-15R complex is known to impact NK
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cell proliferation thus suggesting a possible pathway for NK cell
control in the disease.
NK CELL LICENSING
Natural killer cells are “licensed” to recognize and kill cells that do
not express self-MHC. In 1986, Karre et al. described this phenom-
enon as the“missing self” hypothesis (16). This states that NK cells
are activated to detect and kill cells that are thought to be non-self,
i.e., infected cells or those undergoing neoplastic changes. Over
the last 30 years, a number of authors have demonstrated that NK
cells from MHC-deficient mice and humans do not effectively kill
target cells (17, 18).
Natural killer cell receptors such as KIR have loci that segregate
independently of MHC loci. Thus, in any one individual, some
NK cells do not have a corresponding inhibitory HLA ligand, i.e.,
KIR3DL1+ve cells in a Bw6 homozygote. It is unclear how such
cells could be prevented from killing autologous cells. Yokoyama
et al. proposed that KIR on NK cells must recognize their cognate
HLA ligand in order to acquire functional competence through
licensing (19). An alternate “disarming” hypothesis proposes that
NK cells that fail to recognize MHC class-I via inhibitory KIR
become anergic (20). Hence, paradoxically, an inhibitory recep-
tor interaction appears to be required for an NK cell to acquire
function.
In the context of infection, unlicensed NK cells may become
activated in response to cytokines from infected cells. This
may permit a broader repertoire of NK cells to contribute to
the response to pathogens without the risk of autoimmunity
(21). Moreover, the licensing concept embraces gene dosage, i.e.,
KIR3DL1+ve cells in donors who are homozygous for Bw4 dis-
play increased responsiveness to tumor stimulation compared to
heterozygotes and those who lack the ligand. In contrast, NK cells
lacking KIR3DL1 show no difference in activity (22).
GENETIC STUDIES IN BEHÇET’S DISEASE
Evidence for a genetic association in BD first came about in 1982,
when Ohno et al. published their results suggesting that HLA-B*51
was associated with BD in Japanese patients (23). This association
has become recognized as the most frequently observed genetic
factor in BD and is present in between 13 and 80% of patients
(24). HLA-B51 presents antigen to CD8+ve cytotoxic T cells, but is
also known to interact with the KIR3DL1 via its Bw4 epitope (25)
(Figure 1). KIR interacts with position 7 and 8 of the HLA-bound
peptide and with positions 77–83 of HLA molecules that have the
Bw4 epitope (26, 27). Bw4 is present on a third of all HLA-B alleles
and is defined by leucine at position 82 and arginine at position
83. It is associated with strong inhibition of NK cell activity via
KIR3DL1 interaction. The Bw6 epitope (Ser 77, Asn 80, Leu 81,
Arg 82, and Gly 83) does not interact with KIR3DL1 (28). There is
considerable variation within the KIR haplotype. KIR genes differ
in content and copy number and not all alleles are present in every
individual.
The Bw4 epitope can be found on other HLA alleles associated
with BD, such as HLA-B*2702 (29) as well as those thought to
be protective, such as HLA-B*58 or HLA-A*0301 (30). The asso-
ciation with HLA-B*51 may be due to peptide binding with low
affinity leading to reduced tolerance and/or inefficient NK cell
licensing (31).
FIGURE 1 | Schematic illustrating the potential role of NK cells in
Behçet’s disease. Infection or inflammation at mucocutatneous surfaces
may persist due to dysfunction of the innate immune response in
predisposed individuals. ERAP1 may have a role in processing peptides that
are presented by HLA-class-I molecules. KIR3DL1 inhibits cell-mediated
cytotoxicity via interaction with HLA-B*51. This effect is balanced by
activatory interactions via NKG2D and MICA. Production of cytokines
including IL-10 and IL-15 contribute to abnormal NK cell function leading to
prolonged inflammation and further episodes. NK cell, natural killer cell;
ERAP, endoplasmic reticulum aminopeptidase 1; HLA, human leukocyte
antigen; KIR, killer immunoglobulin-like receptor; MICA, MHC class-I
polypeptide-related sequence A; NKG2D, natural killer group 2; receptor D;
IL, interleukin.
Four genome-wide association studies (GWAS) investigating
genetic associations in BD have been carried out to date and all
have confirmed association with the MHC region (32–35). In the
last 3 years, data from these studies have been subjected to imputa-
tional analysis (a process using known haploytpes to allow testing
of untyped genetic variants for association with a trait of inter-
est) and a number of genes were found to achieve significance
including: C–C motif chemokine receptor 1 (CCR1), STAT4, killer
cell lectin-like receptor subfamily C (KLRC4), and endoplasmic
reticulum amino peptidase 1 (ERAP1) (35). All of these genes
are involved in cytotoxicity in some capacity. Of note, KLCRC4
is located on a haplotype block, which also codes for other NK
cell receptors, such as NKG2D (36). A functional role for this
gene has yet to be established, but there is evidence for reduced
cytotoxicity in NK cells from patients carrying this haplotype
(37) (Table 1).
In 2013, Hughes et al. closely examined the HLA region using
deep sequencing, and identified rs116799036, a SNP in the HLA-
B*51 promoter region, 24 kb upstream from HLA-B*51 and 18 kb
upstream of MICA, which was found to achieve genome-wide
significance even when controlled for the effects of HLA-B*51.
Furthermore, when controlling for the effects of rs116799036, the
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Table 1 | Genes implicated in the pathogenesis of Behçet’s disease
and their potential mechanisms of action.
Genes implicated in
the pathogenesis
of BD
Mechanism of
interaction
with NK cells
Overall effect on
NK cells
HLA-B*51
(HLA-B*5101) (38)
Interaction with KIR3DL1
via the Bw4 epitope (39)
Inhibition
MICA (MICA*009)
(40–43)
Interaction with
NKG2D (44)
Activation
IL-23R/IL-12Rβ2
(33, 34)
Down regulated gene
expression of
IL-12Rβ2 (45)
Rendered hyporeactive
to IL-12 with deficient
IFNγ production
IL-10 (33, 34) Unknown Possible effect on
increasing pro-
inflammatory cytokine
expression and
increasing cytotoxicity
KLRC4 (35) Unknown Possible effect on
reducing peripheral
blood cytotoxicity in
NK cells (37)
CCR1 (35)
ERAP1 (35) Trims proteasome-
derived peptides before
loading into HLA-class-I
binding groove
Alters recognition of
HLA-class-I by KIR
association with HLA-B*51 was abrogated, suggesting that the
association between HLA-B*51 and BD may not be causal (38).
However, this finding was not replicated in a larger cohort, which
confirmed HLA-B*51 as the strongest association (46). In addition,
this study found that HLA-A*03, HLA-B*15, HLA-B*27, HLA-
B*49, HLA-B*57, and HLA-A*26 each contributed independently
to the risk of developing BD. This data support HLA-B*51 as the
strongest association in BD.
FUNCTIONAL ACTIVITY OF NK CELLS IN BEHÇET’S DISEASE
In order to investigate the functional activity of NK cells in BD,
Yamaguchi et al. assessed 47 patients with BD (10 with active dis-
ease). CD69+ve NK cells were significantly increased in active BD,
but their cytotoxic function was similar to inactive and control
subjects. IL-12Rβ2 mRNA levels were decreased in NK cells from
patients with active BD, compared to inactive patients or healthy
controls. Furthermore, NK cells from inactive patients suppressed
IFNγ production by CD4+ve T cells from patients with active dis-
ease (45). These findings suggest that while NK cells proliferate
in active BD, they may be rendered hyporesponsive due to an
abnormality in IL-12 signaling. Hamzaoui et al. also described
hyporesponsive NK cells in bronchoalveolar lavage (BAL) samples
from patients with pulmonary BD. The authors did not exam-
ine the effects of IL-12, but instead focused on IL-2/IL-15Rβ
(CD122), which was found to have reduced surface expression.
CD122 is shared by the IL-15 receptor, which is partly responsible
for maintenance and cytotoxicity of NK cells (47).
Treusch et al. evaluated the effect of IFNα-2a on the NK cell
repertoire in BD. IFNα-2a is often used as a second or third line
therapeutic agent in BD, particularly in the presence of ocular
disease. The investigators found a significant decrease in circulat-
ing NK cells in active BD patients after treatment compared to
controls. This reduction may be a direct effect of IFNα-2a or sec-
ondary induction of remission of BD. IFNα-2a has been postulated
to work directly on NK cells by inducing apoptosis and indirectly
by reducing IL-18, IL-12, and/or IL-21 (48).
NK CELL RECEPTORS
KILLER IMMUNOGLOBULIN-LIKE RECEPTORS
In humans, receptors belong to either the immunoglobulin-like
superfamily (IgSF) or the C-type lectin-like receptor (CTLR)
superfamily. KIR are part of the IgSF and have specific ligands
in the HLA-class-I family (49).
Inhibitory KIR (i.e., KIR2DL and KIR3DL), contain
immunoreceptor tyrosine-based inhibition motifs (ITIMs) in
their cytoplasmic domains. Activating KIR molecules (i.e.,
KIR2DS and KIR3DS) lack ITIMs and have a charged residue in
their transmembrane domains, which likely pair with the DAP12
signaling adapter. KIR2DL4 is unusual as it consists of a long intra-
cellular region but only one ITIM and a positively charged amino
acid in the transmembrane region. Unlike other clonally distrib-
uted KIR, KIR2DL4 is transcribed by all NK cells and acts as an
activating receptor on recognition of HLA-G (50, 51). Inhibitory
KIR consistently binds with a higher affinity than their activating
counterparts (52).
Saruhan-Direskeneli et al. found no association of KIR3DL1
expression on NK or T cells in patients with BD, a finding not
altered by the presence of Bw4 motif in patients (53). Similar
results were found by Middleton et al. after analyzing 14 KIR genes
in a cohort of Turkish patients and ethnically matched controls
using a sequence-specific oligonucleotide probe (SSOP) method.
They reported an increased frequency of KIR3DL1 and its lig-
and Bw4 (p= 0.0003) and a corresponding decreased frequency of
KIR3DL1 without Bw4 (p= 0.00004) in patients compared to con-
trols. However, this difference was abrogated when the presence of
HLA-B*51 was controlled for (p= 0.7075) (54).
The frequency of 16 KIR genes (2DL1, 2DL2, 2DL3, 2DL4,
2DL5, 3DL1, 3DL2, 3DL3, 2DS1, 2DS2, 2DS3, 2DS4, 2DS5, 3DS1,
2DP1, and 3DP1) was assessed in Korean patients with either
HLA-B27-associated ankylosing spondylitis and uveitis or BD
related uveitis. In the patients with ankylosing spondylitis, the fre-
quency of KIR3DL1 was significantly lower than healthy controls
(p= 0.043), while there was no difference in patients with BD (55).
These studies support a role for KIR3DL1 and Bw4 in BD;
however, there is currently insufficient evidence to suggest that
this is via KIR3DL1–HLA-B51 interaction. The KIR cluster is
highly polymorphic, second only to the HLA in complexity and
is an unsuitable candidate for GWAS analysis as SNP probes
targeting the region are unable to bind due to allelic and copy
number variation within the gene. Other methods including tar-
geted sequencing and functional analysis of different alleles must
be explored further.
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CD94/NKG2
The CD94/NKG2 heterodimer is a member of the CTLR family
and recognizes HLA-E (56). It is thought that CD94/NKG2 work in
conjunction with KIR by responding to changes in HLA expression
and can also transduce both activating and inhibitory signals (57).
The ligand for CD94/NKG2A is the non-classical HLA-E. Peptides
bound to HLA-E function as modulators of NK cell activity. The
NKG2D homodimer, is expressed at various levels on NK cells and
recognizes MICA and UL16-binding protein (ULBP) leading to
NK cell activation through DAP10 signaling.
Saruhan-Direskeneli et al. found CD94 expression was
increased on CD56+CD16+ve and CD56+CD3+ve NK cells in
patients with BD (53). It has been subsequently demonstrated
that both CD94 (c.-134*T ) and NKG2A (c.-4258*C, c.338-90*G)
polymorphisms are associated with reduced risk of BD, an effect
enhanced when combined with expression of HLA-E*0101. Indi-
viduals without this genotype had nearly a fivefold increased risk of
developing BD. Furthermore, the NKG2C c.305*T polymorphism
resulted in an increased rate of both ocular disease and arthritis
(p= 0.0001), whereas the CD94 c.-134*A polymorphism was asso-
ciated with oral, skin, genital, and gastrointestinal manifestations
(58). Of note, HLA-E binds peptides derived from HLA-class-1
molecules and are also recognized by NK cells via CD94/NKG2A,
resulting in an inhibition of cell lysis, thus providing another
mechanism for NK cell regulation (59).
While frequently overlooked in the field of BD, HLA-E, and
HLA-G have important roles in regulating inflammation. HLA-E
is an activator of NK cells via its interaction with CD94/NKG2A
and HLA-G inhibits the cytolytic activities of NK cells via its
interaction with KIR2DL4 and LIR-1/LIR-2. A study in Korean
patients with BD indicated that the variants; HLA-E*0101 and
HLA-G*010101 (p= 0.0002, OR 0.7, p= 0.002, OR 0.7, respec-
tively) were associated with a reduced risk of developing the
disease, whereas HLA-E*010302, HLA-G*010102G*0105N alleles,
and 3741_3754ins14bp were all associated with an increased risk of
BD (p< 0.0001, OR 1.6; p= 0.002, OR 1.8; p= 0.024, OR= 2.0;
and p= 0.003, OR 1.4, respectively). This data indicates that tar-
get cells expressing HLA-E*0101 and HLA-G*010101 are protected
against NK and CD8+ve cell-mediated cytotoxicity. Conversely
polymorphisms in HLA-E and HLA-G may lead to an imbalance
of lymphocyte functions and to the development of BD (60).
MICA IN BEHCET’S DISEASE
MICA is a stress-induced antigen and is recognized by the lym-
phoid stress surveillance system. It is a ligand for NKG2D, and
involved in NK cell activation (Figure 1). While it is generally
agreed that the association between MICA and BD is largely due
to linkage disequilibrium (LD) with HLA-B*51 (61–63), MICA
may have an independent functional role in disease pathogene-
sis. In Korean patients, MICA*A6 homozygosity was associated
with BD in both HLA-B*51+ve and HLA-B*51−ve patients. The
authors also assessed the susceptibility risk of MICA*A6 homozy-
gosity for BD in HLA-B*51−ve patients and found an independent
association (p< 0.001, RR-22.27) (64).
The affinity of MICA as a ligand for NKG2D is not uni-
form. Low affinity MICA have a valine at codon 129 and include
MICA*019 and MICA*009 ; these receptors have a 10- to 50-fold
weaker affinity for NKG2D compared to those with methionine in
position 129 (65). Moreover, an individual’s response to different
MICA alleles is “tuned” and maintained over time (44).
Interestingly Munoz-Saa et al. commented that none of their 42
BD patients expressed a high affinity phenotype for NKG2D com-
pared to 14% of controls, whereas other autoimmune diseases such
as anterior uveitis, ankylosing spondylitis, and psoriatic arthritis
are all associated with high affinity alleles (42, 66–68).
The association of MICA and MHC class-I haplotypes with
BD, suggests a major role in the disease for cells regulated by these
molecules including NK cells and subsets of T cells (40, 69).
ENDOPLASMIC RETICULUM AMINOPEPTIDASE
As discussed above, a polymorphism at the ERAP1 locus was asso-
ciated with BD by imputation of GWAS data (35). The most doc-
umented function of ERAP1 and ERAP2 is to trim peptides that
bind to MHC class-I molecules (Figure 1). Different ERAP1 vari-
ants can produce a different peptide pool, which in turn can affect
folding and expression of MHC class-I on the cell surface and CD8
T-cell cytotoxicity. Furthermore, KIR and CD94/NKG2A function
are affected by the peptide bound to MHC class-I (70). At present,
there is no published data reporting the functional effects of endo-
plasmic reticulum aminopeptidase (ERAP) polymorphisms in BD.
Future work addressing this area is warranted.
CONCLUSION
Several potential mechanisms explaining the pathogenesis of BD
involve NK cells:
1. Defects in the NK cell repertoire may permit persistent
viral infections, resulting in a chronic inflammatory response
leading to BD.
2. NK cells lacking appropriate inhibitory KIR (such as KIR3DL1)
may fail to recognize self-MHC and cause autologous tissue
damage (71).
The role of NK cells in the pathogenesis of BD has been greatly
advanced by genetic studies and the association of MICA and
ERAP support involvement of the innate immune system.
However, major challenges remain, such as the lack of associa-
tion between inhibitory KIR receptors and HLA-B51. I. In the last
decade, over 50 new KIR3DL1 allotypes have been described, only
a small proportion of which are present in different world pop-
ulations (28, 72). It would be useful to establish the geographic
spread of KIR3DL1 and correlate it to previously published work
on HLA-B*51 (2).
It is possible that future work investigating KIR3DL1 poly-
morphisms will uncover allotypes previously untested for. Such
studies, carried out in well-defined and characterized cohorts with
adequate numbers to confirm the basic findings, to date, will not
only strengthen the hypotheses outlined in this review but also
create a body of evidence that may lead to potential new therapies.
REFERENCES
1. Sakane T, Takeno M, Suzuki N, Inaba G. Behcet’s disease. N Engl J Med (1999)
341:1284–91. doi:10.1056/NEJM199910213411707
2. Verity DH, Marr JE, Ohno S, Wallace GR, Stanford MR. Behcet’s disease, the silk
road and HLA-B51: historical and geographical perspectives. Tissue Antigens
(1999) 54:213–20. doi:10.1034/j.1399-0039.1999.540301.x
Frontiers in Immunology | NK Cell Biology March 2015 | Volume 6 | Article 134 | 4
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Petrushkin et al. NK cells in BD
3. Azizlerli G, Kose AA, Sarica R, Gul A, Tutkun IT, Kulac M, et al. Preva-
lence of Behcet’s disease in Istanbul, Turkey. Int J Dermatol (2003) 42:803–6.
doi:10.1046/j.1365-4362.2003.01893.x
4. Caligiuri MA. Human natural killer cells. Blood (2008) 112:461–9. doi:10.1182/
blood-2007-09-077438
5. Inngjerdingen M, Kveberg L, Naper C, Vaage JT. Natural killer cell subsets in
man and rodents. Tissue Antigens (2011) 78:81–8. doi:10.1111/j.1399-0039.
2011.01714.x
6. Raulet DH. Interplay of natural killer cells and their receptors with the adaptive
immune response. Nat Immunol (2004) 5:996–1002. doi:10.1038/ni1114
7. Walzer T, Dalod M, Robbins SH, Zitvogel L, Vivier E. Natural-killer cells and
dendritic cells: “l’union fait la force”. Blood (2005) 106:2252–8. doi:10.1182/
blood-2005-03-1154
8. Cooper MA, Fehniger TA, Turner SC, Chen KS, Ghaheri BA, Ghayur T, et al.
Human natural killer cells: a unique innate immunoregulatory role for the
CD56(bright) subset. Blood (2001) 97:3146–51. doi:10.1182/blood.V97.10.3146
9. De Maria A, Bozzano F, Cantoni C, Moretta L. Revisiting human natural killer
cell subset function revealed cytolytic CD56(dim)CD16+ NK cells as rapid pro-
ducers of abundant IFN-gamma on activation. Proc Natl Acad Sci U S A (2011)
108:728–32. doi:10.1073/pnas.1012356108
10. Moretta A, Parolini S, Castriconi R, Bottino C, Vitale M, Sivori S, et al. Function
and specificity of human natural killer cell receptors. Eur J Immunogenet (1997)
24:455–68. doi:10.1046/j.1365-2370.1997.d01-117.x
11. Sivori S, Vitale M, Morelli L, Sanseverino L, Augugliaro R, Bottino C, et al. p46,
a novel natural killer cell-specific surface molecule that mediates cell activation.
J Exp Med (1997) 186:1129–36. doi:10.1084/jem.186.7.1129
12. Choi J, Lee ES, Choi B, Sohn S. Therapeutic potency of poly I:C in HSV-induced
inflammation through up-regulation of IL-15 receptor alpha. Immunobiology
(2013) 218:1119–30. doi:10.1016/j.imbio.2013.03.005
13. Ahn JK, Yu HG, Chung H, Park YG. Intraocular cytokine environment in
active Behcet uveitis. Am J Ophthalmol (2006) 142:429–34. doi:10.1016/j.ajo.
2006.04.016
14. Hamzaoui K, Hamzaoui A, Ghorbel I, Khanfir M, Houman H. Levels of IL-15 in
serum and cerebrospinal fluid of patients with Behcet’s disease. Scand J Immunol
(2006) 64:655–60. doi:10.1111/j.1365-3083.2006.01844.x
15. Curnow SJ, Pryce K, Modi N, Knight B, Graham EM, Stewart JE, et al. Serum
cytokine profiles in Behcet’s disease: is there a role for IL-15 in pathogenesis?
Immunol Lett (2008) 121:7–12. doi:10.1016/j.imlet.2008.07.009
16. Karre K, Ljunggren HG, Piontek G, Kiessling R. Selective rejection of H-2-
deficient lymphoma variants suggests alternative immune defence strategy.
Nature (1986) 319:675–8. doi:10.1038/319675a0
17. Bix M, Liao NS, Zijlstra M, Loring J, Jaenisch R, Raulet D. Rejection of class I
MHC-deficient haemopoietic cells by irradiated MHC-matched mice. Nature
(1991) 349:329–31. doi:10.1038/349329a0
18. Furukawa H, Yabe T, Watanabe K, Miyamoto R, Miki A, Akaza T, et al. Tolerance
of NK and LAK activity for HLA class I-deficient targets in a TAP1-deficient
patient (bare lymphocyte syndrome type I). Hum Immunol (1999) 60:32–40.
doi:10.1016/S0198-8859(98)00097-4
19. Yokoyama WM, Kim S. How do natural killer cells find self to achieve tolerance?
Immunity (2006) 24:249–57. doi:10.1016/j.immuni.2006.03.006
20. Raulet DH. Missing self recognition and self tolerance of natural killer (NK)
cells. Semin Immunol (2006) 18:145–50. doi:10.1016/j.smim.2006.03.003
21. Kim S, Poursine-Laurent J, Truscott SM, Lybarger L, Song YJ, Yang L, et al.
Licensing of natural killer cells by host major histocompatibility complex class
I molecules. Nature (2005) 436:709–13. doi:10.1038/nature03847
22. Kim S, Sunwoo JB, Yang L, Choi T, Song YJ, French AR, et al. HLA alleles deter-
mine differences in human natural killer cell responsiveness and potency. Proc
Natl Acad Sci U S A (2008) 105:3053–8. doi:10.1073/pnas.0712229105
23. Ohno S, Ohguchi M, Hirose S, Matsuda H, Wakisaka A, Aizawa M. Close associ-
ation of HLA-Bw51 with Behcet’s disease. Arch Ophthalmol (1982) 100:1455–8.
doi:10.1001/archopht.1982.01030040433013
24. Gul A. Genome-wide association studies in Behcet’s disease: expectations and
promises. Clin Exp Rheumatol (2011) 29:S3–5.
25. Gumperz JE, Litwin V, Phillips JH, Lanier LL, Parham P. The Bw4 public
epitope of HLA-B molecules confers reactivity with natural killer cell clones
that express NKB1, a putative HLA receptor. J Exp Med (1995) 181:1133–44.
doi:10.1084/jem.181.3.1133
26. Peruzzi M, Parker KC, Long EO, Malnati MS. Peptide sequence requirements for
the recognition of HLA-B*2705 by specific natural killer cells. J Immunol (1996)
157:3350–6.
27. Peruzzi M, Wagtmann N, Long EO. A p70 killer cell inhibitory receptor spe-
cific for several HLA-B allotypes discriminates among peptides bound to HLA-
B*2705. J Exp Med (1996) 184:1585–90. doi:10.1084/jem.184.4.1585
28. Parham P, Norman PJ, Abi-Rached L, Guethlein LA. Variable NK cell receptors
exemplified by human KIR3DL1/S1. J Immunol (2011) 187:11–9. doi:10.4049/
jimmunol.0902332
29. Gul A, Uyar FA, Inanc M, Ocal L, Barrett JH, Aral O, et al. A weak associ-
ation of HLA-B*2702 with Behcet’s disease. Genes Immun (2002) 3:368–72.
doi:10.1038/sj.gene.6363863
30. Montes-Cano MA, Conde-Jaldon M, Garcia-Lozano JR, Ortiz-Fernandez L,
Ortego-Centeno N, Castillo-Palma MJ, et al. HLA and non-HLA genes in
Behcet’s disease: a multicentric study in the Spanish population. Arthritis Res
Ther (2013) 15:R145. doi:10.1186/ar4328
31. Gebreselassie D, Spiegel H, Vukmanovic S. Sampling of major histocompat-
ibility complex class I-associated peptidome suggests relatively looser global
association of HLA-B*5101 with peptides. Hum Immunol (2006) 67:894–906.
doi:10.1016/j.humimm.2006.08.294
32. Fei Y, Webb R, Cobb BL, Direskeneli H, Saruhan-Direskeneli G, Sawalha
AH. Identification of novel genetic susceptibility loci for Behcet’s disease
using a genome-wide association study. Arthritis Res Ther (2009) 11:R66.
doi:10.1186/ar2695
33. Mizuki N, Meguro A, Ota M, Ohno S, Shiota T, Kawagoe T, et al. Genome-
wide association studies identify IL23R-IL12RB2 and IL10 as Behcet’s disease
susceptibility loci. Nat Genet (2010) 42:703–6. doi:10.1038/ng.624
34. Remmers EF, Cosan F, Kirino Y, Ombrello MJ, Abaci N, Satorius C, et al.
Genome-wide association study identifies variants in the MHC class I, IL10,
and IL23R-IL12RB2 regions associated with Behcet’s disease. Nat Genet (2010)
42:698–702. doi:10.1038/ng.625
35. Kirino Y, Bertsias G, Ishigatsubo Y, Mizuki N, Tugal-Tutkun I, Seyahi E,
et al. Genome-wide association analysis identifies new susceptibility loci for
Behcet’s disease and epistasis between HLA-B*51 and ERAP1. Nat Genet (2013)
45:202–7. doi:10.1038/ng.2520
36. Karasneh J, Gul A, Ollier WE, Silman AJ, Worthington J. Whole-genome screen-
ing for susceptibility genes in multicase families with Behcet’s disease. Arthritis
Rheum (2005) 52:1836–42. doi:10.1002/art.21060
37. Hayashi T, Imai K, Morishita Y, Hayashi I, Kusunoki Y, Nakachi K. Identification
of the NKG2D haplotypes associated with natural cytotoxic activity of periph-
eral blood lymphocytes and cancer immunosurveillance. Cancer Res (2006)
66:563–70. doi:10.1158/0008-5472.CAN-05-2776
38. Hughes T, Coit P, Adler A, Yilmaz V, Aksu K, Duzgun N, et al. Identification of
multiple independent susceptibility loci in the HLA region in Behcet’s disease.
Nat Genet (2013) 45:319–24. doi:10.1038/ng.2551
39. Boyington JC, Motyka SA, Schuck P, Brooks AG, Sun PD. Crystal structure of an
NK cell immunoglobulin-like receptor in complex with its class I MHC ligand.
Nature (2000) 405:537–43. doi:10.1038/35014520
40. Yabuki K, Mizuki N, Ota M, Katsuyama Y, Palimeris G, Stavropoulos C, et al.
Association of MICA gene and HLA-B*5101 with Behcet’s disease in Greece.
Invest Ophthalmol Vis Sci (1999) 40:1921–6.
41. Hughes EH, Collins RW, Kondeatis E, Wallace GR, Graham EM, Vaughan RW,
et al. Associations of major histocompatibility complex class I chain-related
molecule polymorphisms with Behcet’s disease in Caucasian patients. Tissue
Antigens (2005) 66:195–9. doi:10.1111/j.1399-0039.2005.00465.x
42. Munoz-Saa I, Cambra A, Pallares L, Espinosa G, Juan A, Pujalte F, et al. Allelic
diversity and affinity variants of MICA are imbalanced in Spanish patients with
Behcet’s disease. Scand J Immunol (2006) 64:77–82. doi:10.1111/j.1365-3083.
2006.01780.x
43. Mizuki N, Meguro A, Tohnai I, Gul A, Ohno S, Mizuki N. Association of
major histocompatibility complex class I chain-related gene A and HLA-B
alleles with Behcet’s disease in Turkey. Jpn J Ophthalmol (2007) 51:431–6.
doi:10.1007/s10384-007-0473-y
44. Shafi S, Vantourout P, Wallace G, Antoun A, Vaughan R, Stanford M, et al.
An NKG2D-mediated human lymphoid stress surveillance response with high
interindividual variation. Sci Transl Med (2011) 3:113ra124. doi:10.1126/
scitranslmed.3002922
www.frontiersin.org March 2015 | Volume 6 | Article 134 | 5
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Petrushkin et al. NK cells in BD
45. Yamaguchi Y, Takahashi H, Satoh T, Okazaki Y, Mizuki N, Takahashi K, et al. Nat-
ural killer cells control a T-helper 1 response in patients with Behcet’s disease.
Arthritis Res Ther (2010) 12:R80. doi:10.1186/ar3005
46. Ombrello MJ, Kirino Y, De Bakker PI, Gul A, Kastner DL, Remmers EF. Behcet
disease-associated MHC class I residues implicate antigen binding and regula-
tion of cell-mediated cytotoxicity. Proc Natl Acad Sci U S A (2014) 111:8867–72.
doi:10.1073/pnas.1406575111
47. Hamzaoui K, Berraies A, Kaabachi W, Ammar J, Hamzaoui A. Pulmonary man-
ifestations in Behcet disease: impaired natural killer cells activity. Multidiscip
Respir Med (2013) 8:29. doi:10.1186/2049-6958-8-29
48. Treusch M, Vonthein R, Baur M, Gunaydin I, Koch S, Stubiger N, et al. Influence
of human recombinant interferon-alpha2a (rhIFN-alpha2a) on altered lympho-
cyte subpopulations and monocytes in Behcet’s disease. Rheumatology (Oxford)
(2004) 43:1275–82. doi:10.1093/rheumatology/keh311
49. Lanier LL. NK cell receptors. Annu Rev Immunol (1998) 16:359–93. doi:10.1146/
annurev.immunol.16.1.359
50. Rajagopalan S, Fu J, Long EO. Cutting edge: induction of IFN-gamma produc-
tion but not cytotoxicity by the killer cell Ig-like receptor KIR2DL4 (CD158d)
in resting NK cells. J Immunol (2001) 167:1877–81. doi:10.4049/jimmunol.167.
4.1877
51. Faure M, Long EO. KIR2DL4 (CD158d), an NK cell-activating receptor with
inhibitory potential. J Immunol (2002) 168:6208–14. doi:10.4049/jimmunol.
168.12.6208
52. Katz G, Markel G, Mizrahi S, Arnon TI, Mandelboim O. Recognition of HLA-
Cw4 but not HLA-Cw6 by the NK cell receptor killer cell Ig-like receptor
two-domain short tail number 4. J Immunol (2001) 166:7260–7. doi:10.4049/
jimmunol.166.12.7260
53. Saruhan-Direskeneli G, Uyar FA, Cefle A, Onder SC, Eksioglu-Demiralp E,
Kamali S, et al. Expression of KIR and C-type lectin receptors in Behcet’s disease.
Rheumatology (2004) 43:423–7. doi:10.1093/rheumatology/keh063
54. Middleton D, Meenagh A, Sleator C, Gourraud PA, Ayna T, Tozkir H, et al. No
association of KIR genes with Behcet’s disease. Tissue Antigens (2007) 70:435–8.
doi:10.1111/j.1399-0039.2007.00929.x
55. Moon SJ, Oh EJ, Kim Y, Kim KS, Kwok SK, Ju JH, et al. Diversity of killer cell
immunoglobulin-like receptor genes in uveitis associated with autoimmune dis-
eases: ankylosing spondylitis and Behcet disease. Ocul Immunol Inflamm (2013)
21:135–43. doi:10.3109/09273948.2012.754905
56. Lee N, Llano M, Carretero M, Ishitani A, Navarro F, Lopez-Botet M, et al. HLA-E
is a major ligand for the natural killer inhibitory receptor CD94/NKG2A. Proc
Natl Acad Sci U S A (1998) 95:5199–204. doi:10.1073/pnas.95.9.5199
57. Winter CC, Gumperz JE, Parham P, Long EO, Wagtmann N. Direct binding
and functional transfer of NK cell inhibitory receptors reveal novel patterns of
HLA-C allotype recognition. J Immunol (1998) 161:571–7.
58. Seo J, Park JS, Nam JH, Bang D, Sohn S, Lee ES, et al. Association of
CD94/NKG2A, CD94/NKG2C, and its ligand HLA-E polymorphisms with
Behcet’s disease. Tissue Antigens (2007) 70:307–13. doi:10.1111/j.1399-0039.
2007.00907.x
59. Borrego F, Ulbrecht M, Weiss EH, Coligan JE, Brooks AG. Recognition of human
histocompatibility leukocyte antigen (HLA)-E complexed with HLA class I sig-
nal sequence-derived peptides by CD94/NKG2 confers protection from nat-
ural killer cell-mediated lysis. J Exp Med (1998) 187:813–8. doi:10.1084/jem.
187.5.813
60. Park KS, Park JS, Nam JH, Bang D, Sohn S, Lee ES. HLA-E*0101 and HLA-
G*010101 reduce the risk of Behcet’s disease. Tissue Antigens (2007) 69:139–44.
doi:10.1111/j.1399-0039.2006.00742.x
61. Tian W, Boggs DA, Ding WZ, Chen DF, Fraser PA. MICA genetic polymor-
phism and linkage disequilibrium with HLA-B in 29 African-American families.
Immunogenetics (2001) 53:724–8. doi:10.1007/s00251-001-0392-x
62. Gao X, Single RM, Karacki P, Marti D, O’Brien SJ, Carrington M. Diversity of
MICA and linkage disequilibrium with HLA-B in two North American popula-
tions. Hum Immunol (2006) 67:152–8. doi:10.1016/j.humimm.2006.02.009
63. Cambra A, Munoz-Saa I, Crespi C, Serra A, Etxagibel A, Matamoros N, et al.
MICA-HLA-B haplotype diversity and linkage disequilibrium in a population
of Jewish descent from Majorca (the Balearic Islands). Hum Immunol (2009)
70:513–7. doi:10.1016/j.humimm.2009.04.005
64. Park SH, Park KS, Seo YI, Min DJ, Kim WU, Kim TG, et al. Association of
MICA polymorphism with HLA-B51 and disease severity in Korean patients
with Behcet’s disease. J Korean Med Sci (2002) 17:366–70. doi:10.3346/jkms.
2002.17.3.366
65. Steinle A, Li P, Morris DL, Groh V, Lanier LL, Strong RK, et al. Interac-
tions of human NKG2D with its ligands MICA, MICB, and homologs of the
mouse RAE-1 protein family. Immunogenetics (2001) 53:279–87. doi:10.1007/
s002510100325
66. Ricci-Vitiani L,Vacca A, Potolicchio I, Scarpa R, Bitti P, Sebastiani G, et al. MICA
gene triplet repeat polymorphism in patients with HLA-B27 positive and nega-
tive ankylosing spondylitis from Sardinia. J Rheumatol (2000) 27:2193–7.
67. Gonzalez S, Brautbar C, Martinez-Borra J, Lopez-Vazquez A, Segal R, Blanco-
Gelaz MA, et al. Polymorphism in MICA rather than HLA-B/C genes is asso-
ciated with psoriatic arthritis in the Jewish population. Hum Immunol (2001)
62:632–8. doi:10.1016/S0198-8859(01)00242-7
68. Amroun H, Djoudi H, Busson M, Allat R, El Sherbini SM, Sloma I, et al. Early-
onset ankylosing spondylitis is associated with a functional MICA polymor-
phism. Hum Immunol (2005) 66:1057–61. doi:10.1016/j.humimm.2005.09.004
69. Mizuki N, Ota M, Kimura M, Ohno S, Ando H, Katsuyama Y, et al. Triplet repeat
polymorphism in the transmembrane region of the MICA gene: a strong asso-
ciation of six GCT repetitions with Behcet disease. Proc Natl Acad Sci U S A
(1997) 94:1298–303. doi:10.1073/pnas.94.4.1298
70. Vivian JP, Duncan RC, Berry R, O’Connor GM, Reid HH, Beddoe T, et al.
Killer cell immunoglobulin-like receptor 3DL1-mediated recognition of human
leukocyte antigen B. Nature (2011) 479:401–5. doi:10.1038/nature10517
71. Takeno M, Shimoyama Y, Kashiwakura J, Nagafuchi H, Sakane T, Suzuki N.
Abnormal killer inhibitory receptor expression on natural killer cells in patients
with Behcet’s disease. Rheumatol Int (2004) 24:212–6. doi:10.1007/s00296-003-
0352-x
72. Tao SD, He YM, Ying YL, He J, Zhu FM, Lv HJ. KIR3DL1 genetic diversity
and phenotypic variation in the Chinese Han population. Genes Immun (2014)
15:8–15. doi:10.1038/gene.2013.55
Conflict of Interest Statement: The authors declare that the research was conducted
in the absence of any commercial or financial relationships that could be construed
as a potential conflict of interest.
Received: 08 December 2014; accepted: 10 March 2015; published online: 24 March
2015.
Citation: Petrushkin H, Hasan MS, Stanford MR, Fortune F and Wallace GR (2015)
Behçet’s disease: do natural killer cells play a significant role? Front. Immunol. 6:134.
doi: 10.3389/fimmu.2015.00134
This article was submitted to NK Cell Biology, a section of the journal Frontiers in
Immunology.
Copyright © 2015 Petrushkin, Hasan, Stanford, Fortune and Wallace. This is an open-
access article distributed under the terms of the Creative Commons Attribution License
(CC BY). The use, distribution or reproduction in other forums is permitted, provided
the original author(s) or licensor are credited and that the original publication in this
journal is cited, in accordance with accepted academic practice. No use, distribution or
reproduction is permitted which does not comply with these terms.
Frontiers in Immunology | NK Cell Biology March 2015 | Volume 6 | Article 134 | 6
